235

46 - novembre 2018 - Minuti correction appears in N Engl J Med. 2012;366(22):2137]. N Engl J Med. 2012; 366(11):981-990. 51. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life ef- fectsofprostate-specificantigenscreening.NEnglJMed.2012;367(7):595- 605. 52. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific anti- gen:prospectiveevaluationwithinProtecTstudy.BMJ .2012;344:d7894. 53. National Cancer Institute. SEER stat fact sheets: cervix uteri can- cer. http://seer.cancer.gov/statfacts/html/cervix.html. Accessed De- cember 15, 2015. 54. LeydenWA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9):675-683. 55. BenardVB, EhemanCR, LawsonHW, et al. Cervical screening in theNational Breast andCervical Cancer EarlyDetectionProgram, 1995-2001. Obstet Gynecol. 2004;103(3):564-571. 56. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for cervical cancer: a decision analysis for the U.S. Preventive Serv- ices Task Force. http://www.ncbi.nlm.nih.gov/books/NBK92546 /pdf/Bookshelf_NBK92546.pdf. Accessed December 15, 2015. 57. Fox J, RemingtonP, Layde P, KleinG.The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Am J Obstet Gynecol. 1999;180(5):1104-1109. 58. Pearce KF, Haefner HK, Sarwar SF, NolanTE. Cytopathologi- cal findings on vaginal Papanicolaou smears after hysterectomy for benigngynecologic disease.NEngl JMed. 1996;335(21):1559-1562. 59. BenardVB,Thomas CC, King J,Massetti GM, Doria-RoseVP, Saraiya M; Centers for Disease Control and Prevention (CDC). Vital signs: cervical cancer incidence, mortality, and screening— United States, 2007-2012.MMWR Morb Mortal Wkly Rep. 2014;63(44):1004-1009. 60. RoyceTJ, Hendrix LH, StokesWA, Allen IM, Chen RC. Can- cer screening rates in individualswithdifferent life expectancies. JAMA InternMed. 2014;174(10):1558-1565. 61. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann InternMed. 2008;149(9):627- 637. 62. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149(9): 659-669. 63. Tang V, BoscardinWJ, Stijacic-Cenzer I, Lee SJ. Time to bene- fit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials [published correction appears in BMJ. 2015;350:h2228]. BMJ. 2015;350:h1662. 64. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M. Ad- verse events in older patients undergoing colonoscopy: a systematic reviewandmeta-analysis. Gastrointest Endosc. 2011;74(4):885-896. 65. Goodwin JS, Singh A, Reddy N, Riall TS, Kuo YF. Overuse of screening colonoscopy in theMedicare population. Arch InternMed. 2011; 171(15):1335-1343. 66. van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, vanBallegooijenM, Zauber AG. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann InternMed. 2014;160(11):750-759. 67. Humphrey LL,DeffebachM, PappasM, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update theUS Preventive ServicesTask Force recommendation. Ann InternMed. 2013;159(6):411-420. 68. AberleDR, Adams AM, BergCD, et al.; National Lung Screen- ingTrial ResearchTeam. Reduced lung-cancer mortality with low- dosecomputedtomographicscreening.NEnglJMed.2011;365(5):395- 409. 69. de KoningHJ,Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a compar- ativemodeling study for theU.S. Preventive ServicesTask Force. Ann InternMed. 2014;160(5):311-320. 70. BlackWC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in theNational Lung ScreeningTrial. NEngl JMed. 2014; 371(19):1793-1802. 71. HaggstromDA, Klabunde CN, Smith JL, Yuan G. Variation in primary care physicians’ colorectal cancer screening recommen- dationsbypatientageandcomorbidity.JGenInternMed.2013;28(1):18- 24. 72. SchonbergMA, RamananRA,McCarthy EP,MarcantonioER. Decision making and counseling around mammography screening for women aged80 or older. JGen InternMed. 2006;21(9):979-985. 73. Lewis CL, Griffith J, PignoneMP, GolinC. Physicians’ decisions about continuing or stopping colon cancer screening in the elderly: a qualitative study. J Gen InternMed. 2009;24(7):816-821. 74. Torke AM, Schwartz PH, Holtz LR,Montz K, SachsGA. Older adults and forgoing cancer screening: “I think it would be strange”. JAMA InternMed. 2013;173(7):526-531. 75. Lewis CL, Kistler CE, Amick HR, et al. Older adults’ attitudes about continuing cancer screening later in life: a pilot study inter- viewing residents of two continuing care communities. BMCGeri- atr. 2006;6:10. 76. Ahalt C, Walter LC, Yourman L, Eng C, Pérez-Stable EJ, Smith AK. “Knowing is better”: preferences of diverse older adults for discussing prognosis. J Gen InternMed. 2012;27(5):568-575. 77. Torke AM, Schwartz PH, Holtz LR,Montz K, Sachs GA. Care- giver perspectives on cancer screening for persons with dementia: “why put them through it?”. J AmGeriatr Soc. 2013; 61(8):1309- 1314. 78. StaceyD, Légaré F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. CochraneDatabase Syst Rev. 2014;1:CD001431. 79. SchonbergMA,Walter LC.Talking about stopping cancer screen- ing-not so easy. JAMA InternMed. 2013;173(7):532-533. 80. Albert RH, Clark MM. Cancer screening in the older patient. AmFamPhysician. 2008;78(12):1369-1374.